A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302
A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Japanese Pediatric Subjects With Short Bowel Syndrome Who Completed SHP633-302
Sponsor: Shire
Listed as NCT03268811, this PHASE3 trial focuses on Short Bowel Syndrome and remains completed. Sponsored by Shire, it has been updated 15 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2022 — Jun 2022 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 10 earlier versions
-
Jan 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Aug 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE3
-
Mar 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE3
Status: Enrolling By Invitation → Active Not Recruiting
-
Nov 2019 — Mar 2020 [monthly]
Enrolling By Invitation PHASE3
Status: Recruiting → Enrolling By Invitation
-
May 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Nov 2018 — May 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE3
First recorded
Aug 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shire
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .